Stephane Bancel - 01 Mar 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Chief Executive Officer, Director
Signature: /s/ James Dillon, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 01 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2026, 16:19:47 UTC
Previous filing: 26 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bancel Stephane	Chief Executive Officer, Director	C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE	/s/ James Dillon, as Attorney-in-Fact	03 Mar 2026	0001443340

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MRNA	Common Stock						6,187,791	01 Mar 2026	Direct
holding	MRNA	Common Stock						9,210,686	01 Mar 2026	See Footnote	F1
holding	MRNA	Common Stock						6,564,880	01 Mar 2026	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Stock Option (Right to Buy)	Award	$0	+250,932		$0.000000	250,932	01 Mar 2026	Common Stock	250,932	$53.57	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F2	These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F3	25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.